| Reshma Kewalramani |
CEO & President, Director |
$45,221,721 |
+$3,895,768 |
+9.4% |
06 Aug 2025 |
| Amit Sachdev |
EVP Chief Patient & Ext Af Off |
$33,267,739 |
|
|
26 Feb 2025 |
| Stuart A. Arbuckle |
Evp, Coo |
$28,594,582 |
|
|
01 Jul 2025 |
| BRUCE I. SACHS |
Director |
$23,885,139 |
+$1,948,416 |
+8.9% |
15 Oct 2025 |
| Ourania Tatsis |
EVP, Chief Reg. & Quality Off. |
$21,056,382 |
-$6,291,809 |
-23% |
03 Dec 2025 |
| CHARLES F. WAGNER JR |
Evp, Co & Fo |
$17,391,225 |
-$8,033,000 |
-32% |
03 Dec 2025 |
| Carmen Bozic |
EVP and CMO |
$15,668,379 |
|
|
26 Feb 2025 |
| Bastiano Sanna |
EVP, Cell & Genetic Therapies |
$13,426,165 |
|
|
05 May 2023 |
| DAVID ALTSHULER |
EVP, Chief Scientific Officer |
$9,887,207 |
-$6,420,269 |
-39% |
15 May 2025 |
| Duncan McKechnie |
EVP, Chief Commercial Officer |
$7,420,767 |
|
|
01 Jul 2025 |
| Edward Morrow Atkinson III |
EVP, Chief Technical Ops. Off. |
$7,323,542 |
-$3,999,263 |
-35% |
17 Nov 2025 |
| Jonathan Biller |
EVP and Chief Legal Officer |
$6,872,394 |
-$2,769,093 |
-29% |
03 Dec 2025 |
| Joy Liu |
SVP, General Counsel |
$4,025,167 |
|
|
15 Aug 2022 |
| Kristen Ambrose |
SVP & Chief Accounting Officer |
$3,762,540 |
-$1,363,231 |
-27% |
26 Feb 2025 |
| DIANA MCKENZIE |
Director |
$3,594,392 |
|
|
01 May 2025 |
| Alan M. Garber |
Director |
$3,583,758 |
|
|
01 May 2025 |
| Terrence C. Kearney |
Director |
$2,995,241 |
|
|
01 May 2024 |
| LLOYD CARNEY |
Director |
$2,632,155 |
|
|
19 Nov 2025 |
| JEFFREY M. LEIDEN |
Executive Chairman, Director |
$2,378,846 |
-$60,942,657 |
-96% |
03 Dec 2025 |
| Suketu Upadhyay |
Director |
$2,222,387 |
|
|
15 Oct 2025 |
| Sangeeta N. Bhatia |
Director |
$1,765,239 |
-$305,204 |
-15% |
27 Aug 2025 |
| Nancy Thornberry |
Director |
$1,113,486 |
|
|
01 May 2025 |
| Jennifer Schneider |
Director |
$831,889 |
|
|
01 May 2025 |
| MARGARET G. MCGLYNN |
Director |
$283,841 |
|
|
01 May 2023 |
| Yuchun Lee |
Director |
$283,841 |
|
|
01 May 2023 |
| Michel Lagarde |
Director |
$256,199 |
|
|
01 May 2025 |